Published in PLoS One on May 21, 2008
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol (2009) 6.25
Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 4.43
Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal (2010) 2.44
MicroRNA and cancer--focus on apoptosis. J Cell Mol Med (2009) 2.44
The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ (2013) 2.41
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
A 3'-untranslated region (3'UTR) induces organ adhesion by regulating miR-199a* functions. PLoS One (2009) 2.24
Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J (2009) 2.21
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans. Nat Genet (2011) 2.04
Inhibition of microRNA function by antimiR oligonucleotides. Silence (2012) 2.02
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
Myc represses primitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell (2010) 1.90
MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One (2009) 1.88
MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A (2010) 1.80
MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther (2011) 1.77
Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res (2010) 1.77
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76
microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res (2010) 1.76
Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev (2009) 1.74
MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer (2010) 1.72
Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat (2010) 1.61
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene (2011) 1.60
The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One (2008) 1.56
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One (2009) 1.55
MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A (2010) 1.49
Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res (2013) 1.44
The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J (2012) 1.42
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ (2015) 1.38
Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell (2010) 1.31
Micromanaging vascular biology: tiny microRNAs play big band. J Vasc Res (2009) 1.31
Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J (2011) 1.30
Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Mol Cell Biol (2010) 1.29
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol (2010) 1.28
MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis (2012) 1.27
Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) (2011) 1.22
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem (2011) 1.19
Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 1.19
MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des (2009) 1.18
MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci (2012) 1.17
Involvement of microRNAs in physiological and pathological processes in the lung. Respir Res (2010) 1.17
Transcriptional regulation of mammalian miRNA genes. Genomics (2010) 1.16
Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One (2009) 1.15
Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17~92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol (2011) 1.13
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer (2011) 1.11
MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer (2012) 1.11
MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett (2011) 1.11
MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol (2010) 1.10
Integrated microRNA and mRNA expression profiling in a rat colon carcinogenesis model: effect of a chemo-protective diet. Physiol Genomics (2011) 1.10
Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis (2012) 1.10
Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis. Curr Genomics (2010) 1.09
Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs. Genome Biol (2014) 1.08
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res (2009) 1.08
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene (2012) 1.05
Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. Cancer Cell Int (2009) 1.04
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res (2011) 1.03
MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res (2010) 1.01
A novel onco-miR-365 induces cutaneous squamous cell carcinoma. Carcinogenesis (2013) 1.01
microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev (2010) 1.01
Myc transcription factors: key regulators behind establishment and maintenance of pluripotency. Regen Med (2010) 1.00
Deletion of PTENP1 pseudogene in human melanoma. J Invest Dermatol (2011) 1.00
Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep (2012) 0.99
The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J (2012) 0.99
Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem (2013) 0.98
Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. J Biol Chem (2013) 0.98
microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther (2013) 0.98
Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog (2015) 0.97
Modulation of inflammatory markers by miR-146a during replicative senescence in trabecular meshwork cells. Invest Ophthalmol Vis Sci (2010) 0.96
Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA (2012) 0.95
Investigation gene and microRNA expression in glioblastoma. BMC Genomics (2010) 0.95
Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer (2010) 0.94
Right into the heart of microRNA-133a. Genes Dev (2008) 0.94
Myc orchestrates a regulatory network required for the establishment and maintenance of pluripotency. Cell Cycle (2011) 0.94
Small players with big roles: microRNAs as targets to inhibit breast cancer progression. Curr Drug Targets (2010) 0.93
MicroRNA-17~92 is required for nephrogenesis and renal function. J Am Soc Nephrol (2014) 0.93
MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacol Res (2013) 0.92
Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle (2013) 0.92
Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica (2010) 0.91
Caspase-2 is required for DNA damage-induced expression of the CDK inhibitor p21(WAF1/CIP1). Cell Death Differ (2011) 0.91
Hoxb8 regulates expression of microRNAs to control cell death and differentiation. Cell Death Differ (2013) 0.91
Increased expression of microRNA-17 predicts poor prognosis in human glioma. J Biomed Biotechnol (2012) 0.90
miRNA-Based Therapeutic Strategies. Curr Anesthesiol Rep (2012) 0.89
High-throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol (2013) 0.89
The impact of post-transcriptional regulation in the p53 network. Brief Funct Genomics (2012) 0.89
The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med (2009) 0.89
Designing small multiple-target artificial RNAs. Nucleic Acids Res (2010) 0.88
Prioritizing human cancer microRNAs based on genes' functional consistency between microRNA and cancer. Nucleic Acids Res (2011) 0.88
Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci (2014) 0.87
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol (2009) 0.86
MiR-17-5p modulates osteoblastic differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteonecrosis. Exp Mol Med (2014) 0.86
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica (2013) 0.86
MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol (2012) 0.86
MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities. Curr Pathobiol Rep (2013) 0.86
MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation. Oncotarget (2015) 0.86
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int (2012) 0.86
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Human MicroRNA targets. PLoS Biol (2004) 34.51
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
MicroRNA genes are transcribed by RNA polymerase II. EMBO J (2004) 20.65
Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 16.95
Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev (2006) 15.20
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
Neuroblastoma. Lancet (2007) 10.61
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet (2007) 9.25
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J (1998) 7.17
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A (2004) 5.55
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 5.25
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol (2008) 4.76
A developmental view of microRNA function. Trends Biochem Sci (2007) 4.75
Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res (2005) 4.60
p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol (2001) 4.38
Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol (2007) 4.16
MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 4.02
Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature (2000) 3.36
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell (2005) 3.19
Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res (2001) 2.37
Absence of WAF1 mutations in a variety of human malignancies. Blood (1994) 1.95
MicroRNAs in tumorigenesis: a primer. Am J Pathol (2007) 1.83
Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci (2006) 1.69
Absence of p53 gene mutations in primary neuroblastomas. Cancer Res (1993) 1.69
The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A (2007) 1.68
MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene (1999) 1.46
Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res (1999) 1.15
Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res (2006) 1.12
p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol (2001) 1.10
N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene (2003) 1.03
ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res (2003) 0.85
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 4.02
Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol (2005) 3.39
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res (2008) 3.21
Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol (2005) 2.14
A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol (2008) 1.97
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol (2008) 1.68
The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A (2007) 1.68
Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J (2006) 1.59
TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci (2006) 1.55
Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. EMBO J (2011) 1.55
A systems approach reveals that the myogenesis genome network is regulated by the transcriptional repressor RP58. Dev Cell (2009) 1.53
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle (2009) 1.50
Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections. J Urol (2011) 1.50
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol (2003) 1.47
Human hepatic stellate cells are liver-resident antigen-presenting cells. Hepatology (2011) 1.42
Identification of the hemangioblast in postnatal life. Blood (2002) 1.42
MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica (2009) 1.40
Purification, cloning, and characterization of XendoU, a novel endoribonuclease involved in processing of intron-encoded small nucleolar RNAs in Xenopus laevis. J Biol Chem (2003) 1.40
Feasibility and diagnostic agreement in teledermatopathology using a virtual slide system. Hum Pathol (2007) 1.39
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J Exp Med (2004) 1.38
Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res (2002) 1.36
Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia. Am J Pathol (2007) 1.31
European surveillance for West Nile virus in mosquito populations. Int J Environ Res Public Health (2013) 1.31
Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood (2002) 1.30
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A (2011) 1.27
Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood (2004) 1.27
Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood (2002) 1.25
Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol (2008) 1.25
Characterization of a novel Neisseria meningitidis Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Mol Microbiol (2004) 1.24
Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol (2006) 1.22
Homologous transplantation of neural stem cells to the injured spinal cord of mice. Neurosurgery (2005) 1.22
MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. Br J Haematol (2008) 1.22
Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol (2003) 1.21
Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci (2004) 1.19
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica (2005) 1.19
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol (2004) 1.18
Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Mol Microbiol (2006) 1.17
Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res (2011) 1.16
Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer (2005) 1.16
Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res (2005) 1.15
CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol (2004) 1.15
Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J (2010) 1.10
The use of muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children. Eur J Paediatr Neurol (2011) 1.09
Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J (2004) 1.09
Unexplained neonatal respiratory distress due to congenital surfactant deficiency. J Pediatr (2007) 1.09
Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol (2003) 1.09
Control of cross-presentation during dendritic cell maturation. Eur J Immunol (2004) 1.08
Role of PLZF in melanoma progression. Oncogene (2004) 1.07
Comment on "Influence of HLA-C expression level on HIV control". Science (2013) 1.07
Fatal hypertrophic cardiomyopathy and nemaline myopathy associated with ACTA1 K336E mutation. Neuromuscul Disord (2006) 1.06
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06
NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood (2009) 1.05
Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol (2005) 1.05
Chemotherapy and surgery in children with cystic echinococcosis. Pediatr Infect Dis J (2010) 1.05
High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med (2011) 1.04
Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci (2006) 1.04
Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group studies. Cancer (2010) 1.04
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin Cancer Res (2008) 1.03
Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis (2006) 1.03
Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration. J Immunol (2003) 1.02
Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. Mol Immunol (2002) 0.99
Genome-wide approaches for cancer gene discovery. Trends Biotechnol (2011) 0.98
PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene (2002) 0.98
Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis (2007) 0.98
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis (2007) 0.97
Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res (2005) 0.96
Bladder augmentation using acellular collagen biomatrix: a pilot experience in exstrophic patients. Pediatr Surg Int (2012) 0.96
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol (2007) 0.96
Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res (2007) 0.96
Coordinate Nodal and BMP inhibition directs Baf60c-dependent cardiomyocyte commitment. Genes Dev (2013) 0.96
CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun (2009) 0.95
pRb-dependent cyclin D3 protein stabilization is required for myogenic differentiation. Mol Cell Biol (2007) 0.94
HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am J Surg Pathol (2007) 0.94
c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer (2003) 0.94
Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). Biochim Biophys Acta (2005) 0.93
Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood (2005) 0.93
Cystic dysplasia of the rete testis: report of two cases and review of the literature. Pediatr Dev Pathol (2002) 0.93
HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. J Immunol (2008) 0.93
Methylation damage response in hematopoietic progenitor cells. DNA Repair (Amst) (2007) 0.93
NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res (2010) 0.93
Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Invest Ophthalmol Vis Sci (2003) 0.93
HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood (2002) 0.93
A child with painful legs. Lancet (2005) 0.92
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res (2008) 0.92
Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica (2010) 0.91